Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Shokri

Neurology Marietta, OH Medical Doctor

NPI 1851677074 CMS profile 444795

400 Matthew St Ste 211, Marietta, OH 45750

Open in the dashboard

General payments

$22,224

790 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Shokri of Marietta, OH is reported in the CMS Open Payments database as having received $22,224 across 790 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,285 113
2024 General $3,060 147
2023 General $7,939 167
2022 General $5,159 152
2021 General $1,527 78
2020 General $519 28
2019 General $1,735 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Shokri
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to George Shokri were reported at $2,285. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year George Shokri Neurology median Middle half National median
2019 $1,735 $474 $118–$2,177 $163
2020 $519 $367 $82–$2,309 $114
2021 $1,527 $438 $104–$2,547 $132
2022 $5,159 $442 $103–$2,388 $149
2023 $7,939 $464 $119–$2,312 $160
2024 $3,060 $468 $119–$2,323 $164
2025 $2,285 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $6,734 102 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $2,821 33 payments
  3. UCB, Inc. $1,454 75 payments
  4. Biogen, Inc. $1,385 77 payments
  5. SK Life Science, Inc. $1,226 53 payments
  6. Pfizer Inc. $776 51 payments
  7. Lilly USA, LLC $744 38 payments
  8. Celgene Corporation $641 44 payments
  9. Novartis Pharmaceuticals Corporation $621 27 payments
  10. Eisai Inc. $585 31 payments
  11. Other $5,236 259 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,926 773 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,136 11 payments
  3. Education $163 6 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $6,178 79 payments
  2. QULIPTA $6,036 68 payments
  3. NURTEC ODT Primary Care $2,980 40 payments
  4. Briviact $1,050 57 payments
  5. TYSABRI $817 47 payments
  6. NURTEC ODT Pain $762 50 payments
  7. ZEPOSIA $683 46 payments
  8. VUMERITY $575 30 payments
  9. AIMOVIG $544 28 payments
  10. KESIMPTA $504 21 payments
  11. Other $8,205 422 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

2,833

Median for Neurology: 833

Drug cost

$1,113,768

Median for Neurology: $202,670

Branded share of claims

41.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Radicava Ors Edaravone Brand 22 $289,416
Xcopri Cenobamate Brand 103 $117,110
Ubrelvy Ubrogepant Brand 69 $96,661
Botox Onabotulinumtoxina Brand 66 $78,285
Aimovig Autoinjector Erenumab-Aooe Brand 94 $69,699
Qulipta Atogepant Brand 55 $68,460
Nuplazid Pimavanserin Tartrate Brand 15 $62,176
Nurtec Odt Rimegepant Sulfate Brand 53 $58,556
Eliquis Apixaban Brand 74 $50,851
Briviact Brivaracetam Brand 39 $49,500

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$101,374

Medicare's payments for the services billed

Medicare patients

606

Average age 72

Services billed

1,700

337 women, 269 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Depression 42%
Diabetes 40%
Ischemic heart disease 38%
Chronic kidney disease 29%
COPD 28%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
$276 — —
Briviact
$242 39 —
EMGALITY
$234 16 —
Leqembi
$216 — —
UBRELVY
$193 69 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

790 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record